BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 9263704)

  • 1. Insulin resistance in polycystic ovary syndrome.
    Prelevic GM
    Curr Opin Obstet Gynecol; 1997 Jun; 9(3):193-201. PubMed ID: 9263704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and the long-term consequences of polycystic ovary syndrome.
    Bhathena RK
    J Obstet Gynaecol; 2011; 31(2):105-10. PubMed ID: 21281021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperinsulinemia in polycystic ovary disease.
    Arthur LS; Selvakumar R; Seshadri MS; Seshadri L
    J Reprod Med; 1999 Sep; 44(9):783-7. PubMed ID: 10509302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes and the polycystic ovary syndrome.
    Pelusi B; Gambineri A; Pasquali R
    Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity.
    Nácul AP; Andrade CD; Schwarz P; de Bittencourt PI; Spritzer PM
    Eur J Obstet Gynecol Reprod Biol; 2007 Aug; 133(2):191-6. PubMed ID: 17049715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
    Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
    Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associated non-ovarian problems of polycystic ovarian disease: insulin resistance.
    Chang RJ; Geffner ME
    Clin Obstet Gynaecol; 1985 Sep; 12(3):675-85. PubMed ID: 3905162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
    Nardo LG; Patchava S; Laing I
    Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of leptin, androgens and insulin sensitivity on increased GH response to clonidine in lean patients with polycystic ovary syndrome.
    Spritzer PM; Comim FV; Capp E; D'Avila A
    Horm Metab Res; 2005 Feb; 37(2):94-8. PubMed ID: 15778926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome and type 2 diabetes mellitus.
    De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
    Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study.
    Korhonen S; Hippeläinen M; Niskanen L; Vanhala M; Saarikoski S
    Am J Obstet Gynecol; 2001 Feb; 184(3):289-96. PubMed ID: 11228476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome.
    Poretsky L; Piper B
    Obstet Gynecol; 1994 Oct; 84(4):613-21. PubMed ID: 8090402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
    Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
    Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperinsulinemia does not influence androgens/estrogens ratio in patients with polycystic ovarian syndrome.
    Panidis DK; Rousso DH; Matalliotakis IM; Kourtis AI; Vlassis GD; Koumantakis EE
    Int J Fertil Womens Med; 1999; 44(6):301-6. PubMed ID: 10617252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of insulin resistance in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Papavassiliou AG
    Trends Mol Med; 2006 Jul; 12(7):324-32. PubMed ID: 16769248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and adolescent girls with polycystic ovary syndrome.
    Bhattacharya SM; Ghosh M
    J Pediatr Adolesc Gynecol; 2010 Jun; 23(3):158-61. PubMed ID: 19963413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?
    Corbould A
    Diabetes Metab Res Rev; 2008 Oct; 24(7):520-32. PubMed ID: 18615851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.